NZ Lymphoma / Leukaemia Research Review Issue 25

In this issue:

Early response with dasatinib or imatinib in CML
MMR loss as trigger for restarting TKI inhibitor in CML
Adding imatinib to standard regimen in Ph+ ALL
First-line oral vs. IV arsenic formulation for APL
Pidilizumab + rituximab in relapsed FL
Monocyte count at diagnosis as DLBCL prognosticator
First-line bendamustinerituximab vs. R-CHOP/R-CVP
in indolent NHL/MCL NHL/HL occurring during pregnancy
24-month EFS is robust endpoint for disease-related
DLBCL outcomes
Bone marrow MRD persistence predicts FL outcomes

Please login below to download this issue (PDF)